Abstract:Bcl-2 (B cell lymphoma-2) is an anti-apoptotic member of Bcl-2 family and its overexpression causes development of several types of cancer. The BH3 domain of pro-apoptotic and BH3-only proteins is capable of binding to Bcl-2 protein to induce apoptosis. This binding is the basis for the development of novel anticancer drug which would likely antagonize Bcl-2 overexpression. In this study we have identified BH3 domain of Bax (Bax BH3) as potentially the best Bcl-2 antagonist by performing docking of BH3 peptides (peptides representing BH3 domain of pro-apoptotic and BH3-only proteins) into the Bcl-2 hydrophobic groove formed by BH3, BH1 and BH2 domains (also referred as BH3 cleft). To predict the best small antagonist for Bcl-2, three groups of small peptides (pentapeptide, tetrapeptide and tripeptide) were designed and screened against Bcl-2 which revealed the structural importance of a set of residues playing a vital role in interaction with Bcl-2. The docking and scoring function identified KRIG and KRI as specific peptides among the screened small peptides responsible for Bcl-2 neutralization and would induce apoptosis. The applied pharmacokinetic and pharmacological filters to all small peptides signify that only IGD has drug-like properties and displayed good oral bioavailability. However, the obtained binding affinity of IGD to Bcl-2 was diminutive. Hence deprotonation, amidation, acetylation, benzoylation, benzylation, and addition of phenyl, deoxyglucose and glucose fragments were performed to increase the binding affinity and to prevent its rapid degradation. Benzoylated IGD tripeptide (IGD(bzo)) was observed to have increased binding affinity than IGD with acceptable pharmacokinetic filters. In addition, stability of Bcl-2/IGD(bzo) complex was validated by Molecular Dynamics (MD) simulations revealing improved binding energy, salt bridges and strong interaction energies. This study suggests a new molecule that inhibits Bcl-2 associated cancer/tumor regression.

Structure-Based Discovery of an Organic Compound That Binds Bcl-2 Protein and Induces Apoptosis of Tumor Cells

Cell Permeable Bcl-2 Binding Peptides: A Chemical Approach to Apoptosis Induction in Tumor Cells

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Development of 3‐phenyl‐n‐(2‐(3‐phenylureido)ethyl)‐thiophene‐2‐sulfonamide Compounds As Inhibitors of Antiapoptotic Bcl‐2 Family Proteins

A Conserved Hydrophobic Core At Bcl-X(L) Mediates Its Structural Stability And Binding Affinity With Bh3-Domain Peptide Of Pro-Apoptotic Protein

Natural Diterpenoid Compound Elevates Expression of Bim Protein, Which Interacts with Antiapoptotic Protein Bcl-2, Converting It to Proapoptotic Bax-like Molecule

Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.

Discovery and development of thiazolidine-2,4-dione derivatives as Bcl-2/Mcl-1 dual inhibitors

Bcl-2 Family Proteins As Targets for Anticancer Drug Design

Nonlinear regulation of commitment to apoptosis by simultaneous inhibition of Bcl-2 and XIAP in leukemia and lymphoma cells

Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-XL: Role of Non-Hot Spot Residues

Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain

Discovery and optimization of (2-naphthylthio)acetic acid derivative as selective Bfl-1 inhibitor

Structure-Based Design Of Flavonoid Compounds As A New Class Of Small-Molecule Inhibitors Of The Anti-Apoptotic Bcl-2 Proteins

The chemical biology of apoptosis: Revisited after 17 years

Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment

Identification of Compounds Against Anti‐apoptotic Bcl‐2 Protein Using Docking Studies

Induction of Apoptosis and Down-Regulation of Bcl-XL in Cancer Cells by a Novel Small Molecule, 2[[3-(2,3-Dichlorophenoxy)propyl]amino]ethanol.

Selective Covalent Targeting of Anti‐apoptotic BFL‐1 by a Sulfonium‐Tethered Peptide

Experimental Characterization of the Binding Affinities Between Proapoptotic BH3 Peptides and Antiapoptotic Bcl-2 Proteins

Discovery and Development of Thiazolo[3,2-a]pyrimidinone Derivatives As General Inhibitors of Bcl-2 Family Proteins